Download PDF
Klin Padiatr 2011; 223(3): 113-119
DOI: 10.1055/s-0031-1275293
Rapid Communication

© Georg Thieme Verlag KG Stuttgart · New York

Update on Relapses in Unilateral Nephroblastoma Registered in 3 Consecutive SIOP/GPOH Studies – A Report from the GPOH-Nephroblastoma Study Group

Unilaterale Nephroblastome: Neues zu den Rezidiven innerhalb der 3 konsekutiven SIOP/GPOH-Studien. Ein Bericht der GPOH-Nephroblastom-StudiengruppeR. Furtwängler1 , N. Nourkami1 , M. Alkassar1 , D. von Schweinitz2 , J.-P. Schenk3 , C. Rübe4 , S. Siemer5 , I. Leuschner6 , N. Graf1
  • 1Saarland University Hospital, Pediatric Hematology and Oncology, Homburg/Saar, Germany
  • 2Ludwig Maximilian University Hospital, Dr. von Haunersches Children's Hospital, Pediatric Surgery, München, Germany
  • 3Heidelberg University Hospital, Heidelberg, Germany
  • 4Saarland University Hospital, Radiation Oncology, Homburg/Saar, Germany
  • 5Saarland University Hospital, Urology, Homburg/Saar, Germany
  • 6Schleswig-Holstein University, Campus Kiel, Pediatric Pathology, Kiel, Germany
Further Information

Publication History

Publication Date:
20 April 2011 (online)

Also available at
    Permissions and Reprints

Abstract

Introduction: Treatment and stratification of progressive/relapsed unilateral nephroblastoma (PD) has significantly evolved over the last 20 years. Early PD (≤6 months), initial high risk histology, local stage III, multiple site PD and stage IV have been implemented as high risk classification factors and novel drugs have been introduced.

Patients and methods: We analysed all 251 patients having had a unilateral nephroblastoma (Stage I-IV) and progressive disease who had been treated according to SIOP9/GPO (n = 77), SIOP93-1/GPOH (n = 93) and SIOP2001/GPOH (n = 81) initially.

Results: 3y-overall survival (OS) increased from 43% to 61% and 59% respectively (both p<0.01). 3y-OS for localized stage I-III rose from 43% to 65% and 68% respectively while only little improvement can be seen for initial stage IV patients with 43%, 53% and 44% respectively. Multivariate analysis confirmed high risk histology, local stage III, shorter time to PD, combined relapse as independent risk factors. 26 patients had received high-dose chemotherapy showing 64% 3y-OS compared to 54% for all non-transplanted (p=0.11).

Conclusion: Structuring the treatment of progressive nephroblastoma as well as introducing new drugs have improved the outcome significantly. However improvement is depending on the specific risk profile. Very high risk tumours are often resistant to conventional treatment, hence an international uniform treatment concept is needed to achieve conclusive results in this small group.

Zusammenfassung

Einleitung: Die Behandlung und Stratifikation von Progressen/Rezidiven (PD) unilateraler Nephroblastome hat sich in den letzten 20 Jahren weiterentwickelt. Risikofaktoren sowie neue Chemotherapeutika wurden in die Therapiepläne integriert.

Methoden: Wir berichten über die Ergebnisse der Behandlung aller 251 Patienten mit einem Progress oder Rezidiv eines unilateralen Nephroblastoms im Vergleich der 3 Studien SIOP9/GPO (n=77), SIOP93-01/GPOH (n=93) und SIOP2001/GPOH (n=81).

Resultate: Das 3-Jahres-Gesamtüberleben (OS) aller Patienten nahm von 43% auf 61% und 59% zu (p<0,01). Das 3y-OS für lokalisierte Stadien (I–III) nahm von 43% auf 65% und 68% zu, während es für Stadium-IV-Patienten nur geringfügig von 43% auf 53% und 44% zunahm. Als unabhängige Risikofaktoren konnten in der Multivariatanalyse die kürzere Zeit bis zur PD, lokales Stadium III, kombinierte PD und Hochrisikohistologie bestätigt werden. 26 Patienten, die eine Hochdosistherapie erhalten hatten, erreichten eine 3y-OS von 64%, verglichen zu 54% für die restlichen Patienten (p=0,11).

Fazit: Die Strukturierung der Behandlung sowie neue Medikamente haben zu einer deutlichen Verbesserung der Prognose geführt. Patienten der Sehr-hohes-Risiko-Gruppe benötigen neue Therapiestrategien und Medikamente, die nur durch eine internationale Zusammenarbeit validiert werden können.

Key words

unilateral Wilms’ tumor - stem cell transplantation - recurrence - nephroblastoma in adults - high risk relapse - nephroblastoma

Schlüsselwörter

unilateraler Wilms-Tumor - Stammzelltransplantation - Rezidiv - Nephroblastom bei Erwachsenen - Hochrisikorezidiv - Nephroblastom

References

  • 1 Abu Gosh AM, Krailo MD, Goldman SC. et al . Ifosfamide, Carboplatin and Etoposide in children with poor-risk relapsed Wilms’ tumor: a Childens Cancer Group report.  Ann Oncol. 2002;  13 460-469
    CrossrefPubMedGoogle Scholar
  • 2 Adamson PC, Matthay KK, O’Brien M. et al . A Phase 2 trial of all-trans-retinoids acid in combination with interferon-alpha2a in children with recurrent neuroblastoma or Wilms' tumor: A Pediatric Oncology Branch, NCI and Childrens Oncology Group Study.  Pediatr Blood Cancer. 2007;  49 661-665
    CrossrefPubMedGoogle Scholar
  • 3 Benesch M, Windelberg M, Sauseng W. et al . Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors.  Ann Oncol. 2008;  19 807-813
    PubMedGoogle Scholar
  • 4 De Camargo B, Melarango R, Saba e Silva N. et al . Phase II study of Carboplatin as a single drug for relapsed Wilms tumor: experience of the Brazilian Wilms' Tumor Study Group.  Med Ped Oncol. 1994;  22 258-260
    CrossrefPubMedGoogle Scholar
  • 5 DeKraker J, Graf N, Pein F et al For the SIOP Nephroblastoma Trial committee. Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms’ tumour (SIOP93-01 trial): a randomised controlled trial.  Lancet. 2004;  364 1229-1235
    CrossrefPubMedGoogle Scholar
  • 6 Dome JS, Liu T, Krassin M. et al . Improved Survival for patients with recurrent WIlms tumor: the experience at St. Judes Childrens Research Hospital.  J Ped Hematol Oncol. 2002;  24 192-198
    CrossrefPubMedGoogle Scholar
  • 7 Fuchs J, Szavay P, Luithle T. et al . Surgical implications for liver metastases in nephroblastoma – data from the SIOP/GPO study.  Surg Oncol. 2008;  17 33-40
    CrossrefPubMedGoogle Scholar
  • 8 Green DM, Cotton CA, Malogolowkin M. et al . Treatment of Wilms' tumor relapsing after initial treatment with vincristine, 11n dactinomycin D: a report from the National Wilms' Tumour Study Group Ped.  Blood Cancer. 2007;  48 493-499
    PubMedGoogle Scholar
  • 9 Grundy P, Breslow N, Green DM. et al . Prognostic factors for children with recurrent Wilms’ tumor: Results from the second and third national Wilms’ tumor study.  J Clin Oncol. 1989;  5 638-647
    PubMedGoogle Scholar
  • 10 Hale J, Hobson R, Moroz V. et al . Results of UK Children's Cancer and Leukemia Group (CCLG) protocol for relapsed Wilms' tumour (UKWR): unified relapse strategy improves outcome.  Proceeding of the 40th Meeting of international Society of Pediatric Oncology. 2008;;  Page 62, O154 [Abstract].
    PubMedGoogle Scholar
  • 11 Italiano A, Sirvent N, Michiels JF. et al . Tumour response to paclitaxel in an adult with relapsed nephroblastoma.  Lancet Oncol. 2005;  6 252-253
    CrossrefPubMedGoogle Scholar
  • 12 Jacobs S, Fox E, Krailo M. et al . Phase II Trila of Ixabepilone Administered Faily for Five Days in CHildren and Young Adults with Refractory Solid Tumors: A Report from the Children's Oncology Group.  Clin Cancer Res. 2010;  16 750-754
    CrossrefPubMedGoogle Scholar
  • 13 Kremens B, Gruhn B, Klingbiel T. et al . High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma.  Bone Marrow Transplantation. 2002;  30 893-898
    CrossrefPubMedGoogle Scholar
  • 14 Malogolowkin M, Cotton CA, Green DM. et al . Treatment of Wilms' tumor relapsing after initial treatment with vincristine, actinomycin d, and doxorubicin. A report from the National Wilms' Tumor Study Group.  Ped Blood Cancer. 2008;  50 236-241
    CrossrefPubMedGoogle Scholar
  • 15 McGregor LM, Spunt SL, Santana VM. et al . Phase 1 study of an oxaliplatin and Etoposide regimen in pediatric patients with recurrent solid tumors.  Cancer. 2009;  115 655-664
    CrossrefPubMedGoogle Scholar
  • 16 Metzger ML, Stewart CF, Freemann 3rd BB. et al . Topotecan is active against Wilms’ tumor: results of a multi-institutional phase II study.  J Clin Oncol. 2007;  25 3130-3136
    CrossrefPubMedGoogle Scholar
  • 17 Pein F, Michon J, Valteau-Couanet D. et al . High-dose melphalan, etoposide and dactinomycin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: a French Society of Pediatric Oncology study.  J Clin Oncol. 1998;  16 3295-3301
    PubMedGoogle Scholar
  • 18 Pein F, Pinkerton R, Tournade MF. et al . Etoposide in relapsed Wilms' tumour: a Phase II study by the French Society of Pediatric Oncology.  J Clin Oncol. 1993;  11 1478-1481
    PubMedGoogle Scholar
  • 19 Pein F, Rey A, de Kraker J. et al . Multivariate analysis of adverse prognostic factors (APF) in children with recurrent (Rec) Wilms' tumour (WT) after initial treatment according to SOP 6 and SIOP 9 strategies.  Med Pediatr Oncol. 1998;  33 170 , 0–111 [Abstract]
    PubMedGoogle Scholar
  • 20 Pein F, Tournade M-F, Zucker J-M. et al . Etoposide and dactinomycin: A highly effective combination in relapsed or refractory Wilms’ tumor – A phase II study by the French Society of Pediatric Oncology.  J Clin Oncol. 1994;  12 931-936
    PubMedGoogle Scholar
  • 21 Ramanathan RK, Rubin JT, Ohori NP. et al . Dramatic Response of adult Wilms’ Tumor to Paclitaxel and Cisplatin Med.  Pediatr Oncol. 2005;  34 296-298
    PubMedGoogle Scholar
  • 22 Reinhard H, Semler O, Bürger D. et al . Results 12n dac SIOP 93-01/GPOH Trial and Study 12n dact Treatment of Patients with unilateral nonmetastatic Wilms' Tumor.  Klin Pädiatr. 2004;  216 132-140
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Reinhard H, Schmidt A, Furtwängler R. et al . Outcome of relpases of nephroblastoma in patients registered in the SIOP/GPOH trials and studies.  Oncology Reports. 2008;  20 463-467
    PubMedGoogle Scholar
  • 24 Spreafico F, Bisogno G, Collini P. et al . Treatment of high-risk relapsed Wilms'.  Pediatr Blood Cancer. 2008;  51 23-28
    CrossrefPubMedGoogle Scholar
  • 25 Spreafico F, Pritchard Jones K, Malogolowkin MH. et al . Treatment of relapsed Wilms' tumors: lessons learned.  Expert Rev Anticancer Ther. 2009;  9 1807-1815
    CrossrefPubMedGoogle Scholar
  • 26 Spunt SL, Freeman 3rd BB, Billlups CA. et al . Phase I clinical trial of oxaliplatin in children and adolescents with refractory solid tumors.  J Clin Oncol. 2008;  25 2274-2280
    PubMedGoogle Scholar
  • 27 Tournade MF, Lemerle J, Brunat-Mentigny M. et al . Ifosfamide is an active drug in Wilms' tumour: a Phase II study conducted by the French Society of Pediatric Oncology.  J Clin Oncol. 1988;  6 793-796
    PubMedGoogle Scholar
  • 28 Vujanic GM, Sandstedt B, Harms D et al For the SIOP Nephroblastoma Scientific Committee. Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood.  Med Pediatr Oncol. 2002;  38 79-82
    CrossrefPubMedGoogle Scholar
  • 29 Weirich A, Leuschner I, Harms D. et al . Clincal impact of histologic subtypes in localized non-anaplastic nephroblastoma treated according to the trial and study SIOP-9/GPOH.  Ann Oncol. 2004;  15 808-820
    CrossrefPubMedGoogle Scholar
  • 30 Zils K, Furtwängler R, Reinhard H. et al . Consultation within the nephroblastoma trial SIOP 2001/GPOH as part of the workload in the trial office.  Klin Pädiatr. 2008;  220 183-188
    Article in Thieme ConnectPubMedGoogle Scholar

Correspondence

Rhoikos FurtwänglerMD 

Saarland University Hospital

Pediatric Hematology and

Oncology

KK05 Building 9

66421 Homburg/ Saar

Germany

Phone: +49/6841/1628 399

Fax: +49/6841/1628 424

Email: rhoikos.furtwaengler@uks.eu

      >